Metabolic syndrome (MetS) forms a cluster of metabolic dysregulations including insulin
resistance, atherogenic dyslipidemia, central obesity, and hypertension. The pathogenesis …

DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM)
and is based on promoting the incretin effect. Here, the authors have presented a brief …

Individuals with diabetes mellitus (DM) disclose a higher incidence and a poorer prognosis
of heart failure (HF) than non-diabetic people, even in the absence of other HF risk factors …

The discovery of adipokines has revealed adipose tissue as a central node in the interorgan
crosstalk network, which mediates the regulation of multiple organs and tissues. Adipose …

The discovery of incretin-based medications represents a major therapeutic advance in the
pharmacological management of type 2 diabetes mellitus (T2DM), as these agents avoid …

Dipeptydil-peptidase-4 (DPP-4) inhibitors are available as oral anti-hyperglycemic drugs for
the treatment of type 2 diabetes. Their metabolic effect is mediated through sparing incretin …

We performed a review of the literature to determine whether the dipeptidyl peptidase-4
inhibitors (DPP4-I) may have the capability to directly and positively influence diabetic …

Abstract Aims Dipeptidyl peptidase-4 (DPP-4) inhibitors are a novel class of drugs for the
treatment of hyperglycaemia. Preliminary evidence suggests that their antioxidant and anti …

Abstract Dipeptidyl peptidase 4 (DPP-4) inhibitors (commonly referred to as gliptins) are a
novel class of oral antihyperglycaemic agents with demonstrated efficacy in the treatment of …

DPP4 is an ubiquitously expressed cell-surface protease that is shedded to the circulation
as soluble DPP4 (sDPP4). We recently identified sDPP4 as a novel adipokine potentially …